Emerging Therapies for Parkinson’s Disease
Did you know that Parkinson’s disease psychosis (PDP) is diagnosed in about half of all Parkinson’s diseases patients and presents practitioners with significant disease management challenges?
The Journal of Managed Care & Specialty Pharmacy recently published a manuscript written by a panel of experts from neurology, psychiatry, geriatrics, and geropsychiatry as well as thought leaders from several health plans and Magellan Rx Management to discuss management of PDP.
Dr. Maria Lopes, chief medical officer of Magellan Rx Management, noted the importance of this work: “I think that this research is vital to a better understanding of complex diseases, identify opportunities to develop best practices and key insights that can improve patient care and outcomes.”
The panel discussed the challenging nature of Parkinson’s disease and PDP, the role emerging therapies may play in optimizing effective management and the need for essential education for providers and patients regarding PDP and available therapies.